Literature DB >> 2466036

Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.

N H Mulder1, D T Sleijfer, E G de Vries, H Schraffordt Koops, M J Samson, P H Willemse.   

Abstract

Thirty-one patients with disseminated malignant melanoma were treated with a combination chemotherapy of bleomycin, dacarbazine and vindesine. Five complete responses, and five partial remissions occurred. One patient survived for over 2 years without evidence of disease. This combination of drugs may give better results, as far as complete recovery and long-term survival are concerned, than single-agent therapy with dacarbazine.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2466036     DOI： 10.1007/bf00391607

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  8 in total

1.  Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; J M Smit; E G De Vries; P H Willemse; H S Koops
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

2.  The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.

Authors:  D W Young; R S Lever; J S English; R M MacKie
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

3.  Phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma.

Authors:  S P Richman; T M Woodcock; T T Kubota; M S Blumenreich; P S Gentile; J C Allegra
Journal:  Cancer Treat Rep       Date:  1984-11

4.  WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

Authors:  D Glover; J H Glick; C Weiler; K Fox; D Guerry
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

5.  Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.

Authors:  M K Samson; C D Haas; L H Baker; G Cummings
Journal:  Am J Clin Oncol       Date:  1985-04       Impact factor: 2.339

6.  Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.

Authors:  J J Costanzi; W S Fletcher; S P Balcerzak; S Taylor; H J Eyre; R M O'Bryan; M Al-Sarraf; J Frank
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

7.  Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).

Authors:  G J Hill; E T Krementz; H Z Hill
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

8.  Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.

Authors:  H Hochster; M Levin; J Speyer; S Dunleavy; M Harris; D Roses; F Golomb; F Muggia
Journal:  Cancer Treat Rep       Date:  1985-01
  8 in total
  5 in total

1.  Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Authors:  B Jeremic; L Djuric; L Mijatovic
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

3.  Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

Authors:  N H Mulder; P H Willemse; H Schraffordt Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

4.  Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.

Authors:  N H Mulder; E G de Vries; D T Sleijfer; H Schraffordt Koops; P H Willemse
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

5.  Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Authors:  N H Mulder; W T van der Graaf; P H Willemse; H S Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.